Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by prokofievon Sep 20, 2018 10:09am
199 Views
Post# 28654688

RE:RE:Shorts

RE:RE:Shorts

Maybe you shouldn't invest in development stage companies?..

I do not mean to be rude, but you need to be patient to invest in such companies. Typically, these stocks will sleep for a while and investors end up getting paid in a matter of weeks. It is more akin to a step function than a slow grind higher. You might want to get smart and trade around your positions, which is possible for sure, but then again if a stock is up 20% one day will you truly be buying it if your cost if much lower? Difficult to say.

In this case, I believe there are other catalysts besides the FDA approval to get this rolling, but the true value creation will happen in 1Q19. In retrospect, the 6 months wait to get rewarded handsomely will seem like a no brainer. You will also laugh at getting mad the stock moving down $0.50 on no volume.

Perhaps I am wrong, but this is how I see things. What also gives me comfort, is that this stock hasn’t even begun to go through the discovery phase, a process that will start sometimes in 2019 and attract more investors. Combine this with posting huge quarter over quarter growth, and you get the perfect recipe for massive upside. All these CEPs that will be generating no to little revenues pre-FDA approval, will all start generating revenues with their existing volumes post FDA approval. Simple math, 6 clinics * 250 patients per year (one per day… quite conservative) * $35,000 = $52.5M… While I don’t think this will be the reported number (delays, ramp up, etc…) it will be a good run rate to think about the future. Once they get to 25 clinics at 250 patients years (6,250 patients per year, definetely not a stretch), this translates into $218M in annual revenues, compared to the current market capitalization of $226M… This is what I am waiting for, and why I don’t care much for what happens between now and the approval date. Recall, this is only for one indication: mild traumatic brain injury, but they have completed pilot studies for MS, stroke and cerebral palsy.

Prokofiev


Gibraltar wrote: Can't lie...this is getting pretty frustrating. 

I understand the shorts are doing thier thing, but shouldn't we be seeing more of an uptick leading up to the annoucement? 



 

Bullboard Posts